A share price of Bolt Biotherapeutics Inc [BOLT] is currently trading at $5.37, down -0.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BOLT shares have gain 8.17% over the last week, with a monthly amount glided 12.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Equal-Weight on January 06, 2022. On March 02, 2021, SVB Leerink initiated with a Outperform rating and assigned a price target of $36 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on March 02, 2021. Morgan Stanley initiated its recommendation with a Overweight and recommended $45 as its price target on March 02, 2021. Guggenheim started tracking with a Buy rating for this stock on March 02, 2021, and assigned it a price target of $42.
Bolt Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.41 and $12.60. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $5.37 at the most recent close of the market. An investor can expect a potential return of 30.35% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
Trailing Twelve Months sales for Bolt Biotherapeutics Inc [NASDAQ:BOLT] were 5.20M which represents 90.10% growth. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at -1.57%, Pretax Profit Margin comes in at -1.46%, and Net Profit Margin reading is -1.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.98 and Total Capital is -0.83. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.25 points at the first support level, and at 5.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.55, and for the 2nd resistance point, it is at 5.72.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bolt Biotherapeutics Inc [NASDAQ:BOLT] is 3.57. As well, the Quick Ratio is 3.57, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 1.98, the price to book ratio is 0.32.
Transactions by insiders
Recent insider trading involved Nemec Sarah, Senior VP, Finance and PAO, that happened on Jun 06 ’25 when 125.0 shares were purchased. President, CEO and CFO, Quinn William P. completed a deal on Jun 06 ’25 to buy 125.0 shares. Meanwhile, Senior VP, Finance and PAO Nemec Sarah bought 2500.0 shares on Dec 16 ’24.
